Quamine AE, Dray EL, Mohrdieck NR, King CA, Griggs AA, Kline JM, Cho MM, Rinella SP, Tippins KE, Bates PD, Shi L, Song L, Hess NJ, Kearl TJ, Johnson BD, Capitini CM. TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant. J Immunother Cancer. 2025 Dec 12;13(12) PMID: 41386972 PMCID: PMC12699621 SCOPUS ID: 2-s2.0-105024833850 12/13/2025
Cheng X, Wang Y, Johnson B, You M. Mitochondria-targeted strategies in tumor immunity. Front Immunol. 2025;16:1646138 PMID: 41246345 PMCID: PMC12611915 SCOPUS ID: 2-s2.0-105021816240 11/17/2025
Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS. Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. J Clin Oncol. 2025 Jul 10;43(20):2285-2295 PMID: 40163793 SCOPUS ID: 2-s2.0-105010720202 03/31/2025
Eapen M, Malec LM, Armant MA, Johnson BD, Shi Q, Xu H, Du LM, Jerkins JH, Duffy LJ, Bushman FD, Lee C, Petrichenko A, Hematti P, Brazauskas R, Jobe SM, Hari PN, Wilcox DA. Platelet-Targeted Gene Therapy for Hemophilia A with Inhibitor History. N Engl J Med. 2025 Jan 23;392(4):412-414 PMID: 39842018 PMCID: PMC11756741 SCOPUS ID: 2-s2.0-85216608254 01/22/2025
Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O\'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D. Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 Dec 01;29(23):4784-4796 PMID: 37463058 PMCID: PMC10690096 SCOPUS ID: 2-s2.0-85178651085 07/18/2023
Pan J, Xiong D, Zhang Q, Palen K, Shoemaker RH, Johnson B, Sei S, Wang Y, You M. Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention. Front Immunol. 2023;14:1036563 PMID: 36875137 PMCID: PMC9982083 SCOPUS ID: 2-s2.0-85149504680 03/07/2023
Chu Y, Milner J, Lamb M, Maryamchik E, Rigot O, Ayello J, Harrison L, Shaw R, Behbehani GK, Mardis ER, Miller K, Prakruthi Rao Venkata L, Chang H, Lee D, Rosenthal E, Kadauke S, Bunin N, Talano JA, Johnson B, Wang Y, Cairo MS. Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes. J Infect Dis. 2023 Mar 28;227(6):788-799 PMID: 36583990 SCOPUS ID: 2-s2.0-85151044080 12/31/2022
Chu Y, Talano JA, Baxter-Lowe LA, Verbsky JW, Morris E, Mahanti H, Ayello J, Keever-Taylor C, Johnson B, Weinberg RS, Shi Q, Moore TB, Fabricatore S, Grossman B, van de Ven C, Shenoy S, Cairo MS. Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease. Front Immunol. 2022;13:1055497 PMID: 36569951 PMCID: PMC9780682 SCOPUS ID: 2-s2.0-85144637382 12/27/2022
Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN. Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes. Haematologica. 2023 Feb 01;108(2):588-593 PMID: 36200427 PMCID: PMC9890001 SCOPUS ID: 2-s2.0-85147234722 10/07/2022
Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN. Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. Am J Hematol. 2022 Dec;97(12):1580-1588 PMID: 36068950 SCOPUS ID: 2-s2.0-85138335080 09/08/2022